Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), responsible for coronavirus disease 19 (COVID-19), has rapidly spread since December 2019 to become the focus of healthcare systems worldwide. Its highly contagious nature and significant mortality has led to its prioritization as a public health issue. The race to prevent and treat this disease has led to “off-label” prescribing of medications such as hydroxychloroquine, azithromycin, and Kaletra (lopinavir/ritonavir). Currently, there is no robust clinical evidence for the use of these drugs in the treatment of COVID-19, with most, if not all of these medications associated with the potential for QT interval prolongation, torsades de pointes, and resultant drug-induced sudden cardiac death. The aim of this document is to help healthcare providers mitigate the potential deleterious effects of drug-induced QTc prolongation.
Keywords: COVID-19; Drug-induced QTc prolongation; Guidelines; Torsades de pointes.
【저자키워드】 COVID-19, guidelines, Drug-induced QTc prolongation, torsades de pointes, 【초록키워드】 Treatment, coronavirus disease, public health, SARS-CoV-2, coronavirus, Lopinavir/ritonavir, Azithromycin, Mortality, Hydroxychloroquine, Lopinavir, Ritonavir, drug, medications, severe acute respiratory syndrome Coronavirus, Spread, death, respiratory, medication, disease, QT interval, QTc, Kaletra, QTC prolongation, drug-induced, Healthcare system, sudden cardiac death, focus, Healthcare systems, torsades de pointes, acute respiratory syndrome, Healthcare provider, cardiac death, lAbel, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, help, healthcare providers, treat, clinical evidence, contagious, mitigate, Prevent, robust, responsible, deleterious effect, 【제목키워드】 COVID-19 pandemic, clinical, Guidance,